



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03006098.2

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

THIS PAGE BLANK (USPTO)



Anmeldung Nr:
Application no.: 03006098.2
Demande no:

Anmeldetag:
Date of filing: 19.03.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Roche Diagnostics GmbH
Sandhofer Strasse 112-132
68305 Mannheim
ALLEMAGNE
F. HOFFMANN-LA ROCHE AG
Grenzacherstrasse 124
4070 Basel
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

Quality control method for manufacturing biopolymer arrays

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C12Q/

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT SE SI SK TR LI

THIS PAGE BLANK (USPTO)

19. März 2003

WEICKMANN & WEICKMANN

Patentanwälte

European Patent Attorneys · European Trademark Attorneys

EPO - Munich
09
19. März 2003

DIPL.-ING. H. WEICKMANN (bis 31.1.01)
DIPL.-ING. F. A. WEICKMANN
DIPL.-CHEM. B. HUBER
DR.-ING. H. LISKA
DIPL.-PHYS. DR. J. PRECHTEL
DIPL.-CHEM. DR. B. BOHM
DIPL.-CHEM. DR. W. WEISS
DIPL.-PHYS. DR. J. TIESMEYER
DIPL.-PHYS. DR. M. HERZOG
DIPL.-PHYS. B. RUTTENSPERGER
DIPL.-PHYS. DR.-ING. V. JORDAN
DIPL.-CHEM. DR. M. DEY
DIPL.-FORSTW. DR. J. LACHNIT

Our Ref:
29610P EP/WWkt

Applicant:
Roche Diagnostics GmbH
Sandhofer Str. 112 - 132

68305 Mannheim

Quality control method for manufacturing biopolymer arrays

Quality control method for manufacturing biopolymer arrays

Description

5

The invention relates to a quality control method for manufacturing biopolymer arrays comprising the use of detectable protecting groups.

10

The synthesis of nucleic acids and peptides on a solid phase has been an established process for the last 20 years. The most prevalent method of nucleic acid synthesis is the phosphoramidite method of Beaucage and Caruthers, Tetrahedron Lett. 22 (1981), 1859-1862, where the oligonucleotide chain is built up by the repetitive condensation of individual nucleotide building blocks in the 3' or 5' direction. A variety of orthogonal protecting groups are used to protect three reactive nucleotide groups: the ribose sugar 5' hydroxyl group, the amino protecting group of the nucleobases adenine, guanine and cytosine (thymine does not need a protecting group), as well as the phosphate protecting group of the nucleotide 3' phosphate residue. These protecting groups are then cleaved off under varying conditions, either during or after the synthesis. The 4,4'-dimethoxytriphenylmethyl (DMT) group has become the standard for 5' hydroxyl, the 2-cyanoethyl group the standard for phosphate residue and various acyl groups the standard for the amino functions of the nucleobases according to Büchi and Khorana (J. Mol. Biol. 72 (1972), 251-258) and Souveaux (in: "Methods in Molecular Biology" Vol. 26, Chap. 1 Protocol for Oligonucleoside Conjugates, Ed. S. Agrawal, Humana Press Inc., Totowa, N.J. 1994). The DMT group is cleaved off during synthesis in order to generate an hydroxyl group to which the next phosphoramidite can bind. The other named protecting groups remain until the end of the synthesis in order to prevent any side-reactions or by-products. At the end of the synthesis the complete oligonucleotide is completely deprotected

25

20

15

30

largely by means of a base, whereby 2-cyanoethyl and acyl protecting groups are cleaved off.

There are essentially two means of producing biochips: off-chip and on-chip synthesis of oligonucleotide probes. In off-chip synthesis, the oligonucleotide is produced on a commercially available synthesizer using the above-mentioned standard reagents and then immobilized on the chip. In on-chip synthesis, the oligonucleotide is produced directly on the chip using the above-mentioned standard reagents. In the former case, the quality of the oligonucleotide can be analysed by means of analytical processes such as HPLC or mass spectrometry and, where necessary, improved via purification. The later case of on-chip synthesis allows for only limited quality control and purification is not possible. Quality control is normally only possible by means of the covalent binding of a (mainly fluorescent) colouring material at the terminus of the oligonucleotide, which can then be detected and quantified.

There is scarcely any mention in the literature of processes for determining the deprotection degree of oligonucleotides. A first method comprises the detection of nucleobases and 5'-hydroxyl protecting groups on oligonucleotides with monoclonal antibodies, Fu et al., *Analytical Biochemistry* (2002), 306(1), 135-143). Other references describe the use of cleavable, fluorescent protecting groups. These refer, however, to protecting groups for the 5'-hydroxyl group or the phosphate residue, but not for the nucleobase amino groups. In this context, it should be noted that US Patent 6,238,862 B1 describes a fluorescent, photo labile protecting group for the 5'-hydroxyl group used for determining the synthesis efficiency of the DNA synthesis array. Wagner and Pfeleiderer (*Helv. Chim. Act.* 80 (1990), 200-212) describe a nucleobase protecting group which basically has fluorescent properties. However, this group has been developed for other purposes, especially for improved deprotection properties by using a β -elimination reaction process.

As a rule, exact quality controls cannot be carried out with on-chip synthesis. Presently, only the binding of dyes to the terminus of the oligonucleotide gives an indirect indication of the quantity of solid phase oligonucleotide and of the quality of the synthesis. This does not, however, provide any indication of the rate of the deprotection at the end of the synthesis, i.e. whether all 2-cyanoethyl and acyl protecting groups were cleaved off. It is known that, under standard conditions, the nucleobase acyl protecting groups cannot always be quantitatively cleaved off and part of the amino groups therefore remain protected. Complete deprotection of the amino groups is however essential for the optimal application of the chip. Should not all of the amino function protecting groups be cleaved off, a subsequent hybridisation can be decisively impaired, since the formation of Watson-Crick or Hoogsteen base pairs will be inhibited.

Thus, the invention relates to a quality control method for manufacturing biopolymer arrays comprising:

- (a) synthesizing a plurality of different biopolymer species on an array from monomeric or oligomeric building blocks comprising detectable protecting groups;
- (b) optionally carrying out a determination of the detectable protecting groups on the array after synthesis;
- (c) cleaving off the detectable protecting groups, and
- (d) carrying out a determination of the detectable protecting groups on the array after cleavage; in order to determine the efficacy of deprotection.

These simple steps would enable the quality control of the synthesised biopolymers. The main focus is quality control of the completeness of the biopolymer deprotection. The key advantage is that the methodology is non-destructive and requires no further steps once the final deprotection or detection has been carried out. The outcome is an evaluation of the rate of

deprotection as well as of the quality of freely accessible biopolymers for later use.

Generally, the invention relates to the use of detectable protecting groups in the manufacture of biopolymer arrays. The term "biopolymer" as used in the present application particularly relates to nucleic acids such as DNA or RNA or nucleic acid analogues such as peptide nucleic acids (PNA) or locked nucleic acids (LNA) or combinations thereof. The term, however, also relates to peptides and peptide analogues as well as to other biopolymers such as carbohydrates or any combinations thereof. Preferably the biopolymer species are selected from nucleic acids and nucleic acid analogues wherein the detectable protecting groups are coupled to nucleobases, particularly to amino groups of nucleobases.

The term "array" as used in the present application relates to a solid support e.g. a planar or non-planar solid support. The solid support may have a surface selected from metals such as silicon, metal oxides such as silica, glass or plastic or any combination thereof. Preferably the array is a chip.

The method of the present invention comprises synthesizing a plurality of different biopolymer species on the array from monomeric or oligomeric building blocks. For example, nucleic acids may be synthesized from phosphoramidite or phosphonate building blocks as known in the art. The synthesis is a spatially directed synthesis, e.g. a synthesis of different biopolymer species on different locations on the carrier. Methods for spatially directed biopolymer synthesis include, without limitation, light-directed synthesis, microlithography, application by inkjet, microchannel deposition to specific locations and sequestration with physical barriers. In general, these methods involve generating active sites on the carrier, usually by removing protecting groups and coupling to the active site a

monomeric or oligomeric building block which, itself, optionally has a protected active site if further coupling of building blocks is desired.

5 In a preferred embodiment, the synthesis of the biopolymer species is carried out in a manner that the detectable protecting groups remain on the biopolymer species until the synthesis has been terminated. It should be noted, that the synthesis can be carried out using standard protocols.

10 After synthesis has been terminated a first determination of the detectable protecting groups on the array may be carried out. By this means, qualitative and/or quantitative determination of the biopolymer species on the array is possible. The first determination step is preferably a spatially resolved determination step wherein a qualitative and/or quantitative determination of detectable protecting groups is carried out separately on
15 different locations of the array. Techniques for spatially directed detection procedures may comprise the use of spatially resolved detectors e.g. microscopes or detector matrices such as CCD imaging systems allowing a parallel determination on a plurality of locations on the array.

20 After the optional first determination the detectable protecting groups are cleaved off. The cleavage may be carried out by known protocols according to the nature of the respective detection groups e.g. by photochemical methods such as irradiation, or by chemical methods such as acid or base treatment. In this context it should be noted that the
25 detectable protection groups are preferably selected such that they are not cleaved off during the biopolymer synthesis procedure.

30 After the cleavage of the detectable protecting groups a determination of the detectable protecting groups is carried out on the array in order to determine the efficacy of the protection. This determination may be qualitative and/or quantitative. If a first determination is carried out, the difference between the amount of protecting groups before and after

cleavage is an indication of the amount of deprotected biopolymer and thus an indication of the deprotection rate. When no more protecting groups are detected after deprotection the deprotection has been quantitative, otherwise a repetition of deprotection may be necessary.

5

In a first embodiment of the invention the detectable protecting groups are selected from fluorescent groups, e.g. groups comprising pyrene, dansyl, stilbene, rhodamine and/or coumarine moieties. An important feature of the fluorescent groups is that they are stable during oligonucleotide synthesis.

10

For example, the fluorescent moiety may be combined with an acyl, e.g. a tert-butylphenoxyacetyl protecting group or another amino protecting group.

15

In a further embodiment the detectable protecting groups may be selected from radioactively detectable protecting groups. For example, radioactively detectable groups are selected from groups comprising ^{14}C , ^{32}P and ^3H doped moieties which may be combined with a suitable protecting group, e.g. an amino protecting group.

20

In a still further embodiment the detectable protecting groups may be selected from electrochemically detectable protecting groups, e.g. groups comprising ferrocene and/or phenothiazine moieties. These moieties may be combined with suitable protecting groups, e.g. amino protecting groups. The determination of such protecting groups may be carried by electrochemical methods, e.g. voltammetry.

25


30

In a still further embodiment of the present invention the detectable protecting groups may be selected from UV or IR detectable protecting groups, e.g. from groups comprising aromatic nitro moieties, hydroxyl moieties, thiole, thioether or thiophenole moieties, nitrile moieties, isocyanate moieties and/or halo moieties. UV and IR detectable protecting

groups are preferably detectable independently from the biopolymer species which has been synthesised on the array.

In a still further embodiment the detectable protecting groups are selected from bioaffine detectable protecting groups. Bioaffine detectable protecting groups comprise moieties selected from partners of a bioaffine binding pair which can be detected by their specific interaction with the respective other partner of the binding pair. Specific examples of bioaffine detectable protecting groups are protecting groups comprising biotin, digoxin or digoxigenin moieties. Biotin may be detected by its bioaffine interaction with streptavidin or avidin or with anti-biotin-antibodies. Digoxin or digoxigenin may be detected by their specific interaction with respective antibodies.

In an especially preferred embodiment of the present invention the building blocks for the biopolymer synthesis are nucleotide building blocks having the general structural formulae I or II:



wherein R¹ is an hydroxy protecting group,

R² is -H, -(C₁-C₁₀)-alkoxy, -(C₂-C₁₀)-alkenyloxy, -(C₂-C₁₀)-alkynyloxy, -halo, -azido, -NHR₇, -SR₇ or -OR₇, wherein R₇ is a protecting group or a reporter group,

R³ is a phosphate, an H-phosphate or other phosphate analogue group which may contain a protecting group,

B is a nucleobase or a nucleobase analogue,

n is 0 or 1, and

L is a detectable protecting group, e.g. of the structure $-C(O)-R$, when $n = 1$, or $=CH-NR^8R$, when $n = 0$, wherein R is the residue of the reporter group and R^8 is selected from the group consisting of $-(C_1-C_3)$ -alkyl.

In the compounds (I) or (II) the 5' or 3' hydroxy protecting group R^1 is preferably selected from optionally substituted triphenylmethyl groups, e.g. 4,4'-dimethoxy triphenylmethyl or 4-monomethoxy triphenyl, pixyl groups, photocleavable groups, e.g. p-nitrophenylpropoxy carbonyl (NPPOC) or (α -methyl)-6-nitropiperonyloxy carbonyl (MeNPOC), and substituted silyl protecting groups, e.g. tert-butyldimethyl silyl (TBDMS) or tert-butyldiphenyl silyl (TBDPS).

The group R^3 is a phosphate or phosphate analogue group which may contain a protecting group, preferably a phosphitamide group, more preferably a group $-P(R^6)NR^4R^5$, wherein R^4 and R^5 are independently selected from the group consisting of $-H$, $-(C_1-C_{10})$ -alkyl, $-(C_2-C_{10})$ -alkenyl, $-(C_6-C_{22})$ -aryl, or wherein NR^4R^5 can form together with N a 5-6-membered heterocyclic ring,

R^6 is selected from the group consisting of $-(C_2-C_6)$ -alkenyloxy, $-(C_2-C_6)$ alkenyl, $-(C_1-C_6)$ -alkyl, or $-(C_1-C_6)$ -alkoxy,

wherein each group may contain one or several substituents selected from $-halo$, p-nitroaryloxy and $-cyano$ or wherein R^6 is $-H$.

R^6 is most preferably a 2-cyanoethyloxy group.

B is a nucleobase or nucleobase analogue having at least one amino group, e.g. adenine, guanine, cytosine, or a corresponding nucleobase analogue.

The nucleobase or nucleobase analogue is preferably capable of hydrogen bridge formation with a complementary nucleobase after incorporation into a nucleic acid molecule. Suitable nucleobase analogues are mono- and bicyclic heterocycles comprising at least one amino group wherein the

heterocycle is different from natural nucleobases as described by Simons, (Advanced 2001 Chemistry Texts, Nucleoside Mimetics, Gordon and Breach Science Publishers, Amsterdam 2001, Chapter 4), for example aza analogues of naturally occurring nucleobases, wherein a CH-moiety of a purine or a pyrimidine ring is replaced by nitrogen (such as 8-aza-adenosine) or deaza analogues of naturally occurring nucleobases wherein an N atom in the ring is substituted by a CH group (such as 7-deaza-guanosine) or combinations of aza and deaza substitutions (such as 8-aza-7-deaza-guanosine). Further preferred nucleobase analogues are C-nucleosides, e.g. deaza nucleobases wherein the N9 atom of a purine base or the N1 atom of a pyrimidine base respectively is substituted by a carbon atom (in the sp^2 configuration) such as formycine and pseudoisocytidine. Further, suitable nucleobase analogues may carry additional amino groups, e.g. 2-aminoadenosine. Further, the nucleobase or nucleobase analogue may be substituted, wherein the substituent, e.g. a C_1 - C_3 alkyl or alkoxy, a C_2 - C_3 alkenyl or alkenyloxy, a C_2 - C_3 alkynyl or alkynyloxy and/or a halo substituent, is preferably compatible with the formation of hydrogen bridges to a complementary base. Preferred positions for substituents are C5 in pyrimidine bases, C8 in purine bases and C7 in deaza purine bases.

Furthermore, the present invention relates to a nucleic acid synthesis building block having the general structural formulae I or II as described above.

The building blocks are suitable for the production of nucleic acid arrays.

Furthermore, the invention relates to a reagent kit for the synthesis of nucleic acid arrays comprising at least one nucleic acid synthesis building block as described above. For example, the reagent kit may comprise at least two different nucleic acid synthesis building blocks each carrying different detectable protecting groups. The different detectable protecting groups are preferably detectable independent from each other. For

example, the reagent kit may comprise at least two different independently detectable fluorescent protecting groups, or combinations of different embodiments of detectable protecting groups, e.g. fluorescent and bioaffine detectable protecting groups or other combinations of different protecting groups.

Further, the invention shall be explained in more detail by the following Figures.

10 Fig. 1. Fluorescent, pyrene-labelled cytidine building block. The pyrene-containing nucleobase protecting group exhibits fluorescent properties and can therefore be detected by means of optical analysis procedures.

15 If the nucleobase aminofunctions are protected with a cleavable acyl group carrying a biotin or digoxigenin labelled system, then detection can be carried out using streptavidin or anti-digoxigenin.

20 Fig. 2. A cytidine building block with an IR detectable nitro aromatic moiety.

Fig. 3. A cytidine building block with an electrochemically detectable ferrocene moiety.

THIS PAGE BLANK (USPTO)

Claims


1. A quality control method for manufacturing biopolymer arrays
5 comprising
 - (a) synthesizing a plurality of different biopolymer species on an array from monomeric or oligomeric building blocks comprising detectable protecting groups;
 - (b) optionally carrying out a determination of the detectable
10 protecting groups on the array after synthesis;
 - (c) cleaving off the detectable protecting groups, and
 - (d) carrying out a determination of the detectable protecting groups on the array after cleavage; in order to determine the efficacy of deprotection.
- 15 2. The method of claim 1, wherein the detectable protecting groups are selected from fluorescent detectable protecting groups.
3. The method of claim 2, wherein the fluorescent detectable
20 protecting groups are selected from groups comprising pyrene, dansyl, stilben, rhodamine or coumarine moieties.
4. The method of claim 1, wherein the detectable protecting groups are selected from radioactively detectable protecting groups.
- 25 5. The method of claim 4, wherein the radioactively detectable groups are selected from groups comprising ^{14}C , ^{32}P or ^3H doped moieties.
6. The method of claim 1, wherein the detectable protecting groups are
30 selected from electrochemically detectable protecting groups.

7. The method of claim 6, wherein the electrochemically detectable groups are selected from groups comprising ferrocene or phenothiazine moieties.
- 5 8. The method of claim 1, wherein the detectable protecting groups are selected from UV- or IR-detectable protecting groups.
9. The method of claim 8, wherein the UV- or IR-detectable protecting groups are selected from groups comprising aromatic nitro moieties, hydroxyl moieties, thiol, thioether or thiophenol moieties, nitrile
10 moieties, isocyanate or halo moieties.
10. The method of claim 1, wherein the detectable protecting groups are selected from bioaffine detectable protecting groups.
- 15 11. The method of claim 10, wherein the bioaffine detectable protecting groups are selected from groups comprising biotin, digoxin or digoxigenin moieties.
- 20 12. The method of any one of claims 1-11, wherein the biopolymer species are selected from nucleic acids, nucleic acid analogues, peptides and peptide analogues.
13. The method of claim 12, wherein the biopolymer species are
25 selected from nucleic acids and nucleic acid analogues and wherein the detectable protecting groups are coupled to nucleobases.
14. The method of claim 13 wherein the detectable protecting groups are coupled to amino groups of nucleobases.


15. The method of any one of claims 12-14, wherein the building blocks for the biopolymer synthesis are nucleotide building blocks having the general structural formulae (I) or (II):

5

10



I



II

15

20



wherein R¹ is an hydroxy protecting group,
R² is -H, -(C₁-C₁₀)-alkoxy, -(C₂-C₁₀)-alkenyloxy, -(C₂-C₁₀)-alkynyloxy, -
halogen, -azido, -NHR₇, -SR₇ or -OR₇, wherein R₇ is a protecting
group or a reporter group,
R³ is a phosphate, an H-phosphonate or other phosphate analogue
group which may contain a protecting group,
B is a nucleobase or a nucleobase analogue,
n is 0 or 1, and
L is a detectable protecting group.

25

30

16. The method of claim 15, wherein R¹ is selected from optionally
substituted triphenylmethyl groups, e.g. 4,4'-dimethoxy
triphenylmethyl or 4-monomethoxy triphenyl, pixyl groups,
photocleavable groups, e.g. p-nitrophenylpropoxy carbonyl (NPPOC)
or (α-methyl)- 6-nitropiperonyloxy carbonyl (MeNPOC), and
substituted silyl protecting groups, e.g. tert-butyldimethyl silyl
(TBDMS) or tert-butyldiphenyl silyl (TBDPS).

17. The method of claims 15 or 16, wherein R^3 is a phosphite amide group.
18. The method of claim 12 wherein R^3 is the group $-P(R^6)-NR_4R_5$ wherein R^4 and R^5 are independently selected from the group consisting of $-H$, $-(C_1-C_{10})$ -alkyl, $-(C_2-C_{10})$ -alkenyl, $-(C_6-C_{22})$ -aryl, or wherein NR_4R_5 can form together with N a 5-6-membered heterocyclic ring, and R^6 is selected from the group consisting of $-(C_2-C_6)$ -alkenyloxy, $-(C_2-C_6)$ -alkenyl, $-(C_1-C_6)$ -alkyl, $-(C_1-C_6)$ -alkoxy, wherein each group may contain one or several substituents selected from $-halo$, p -nitroaryloxy and $-cyano$ or wherein R^6 is $-H$.
19. The method of claim 18, wherein R^6 is a 2-cyanoethyloxy group.
20. The method of any one of claims 15-19 wherein L has the structure $-C(O)-R$, when $n=1$, or $=CH-NR^8R$ when $n=0$, wherein R is the residue of the protecting group and R^8 is selected from H and $-(C_1-C_3)$ -alkyl.
21. The method of any one of claims 15-20, wherein B is selected from adenine, guanine, cytosine, aza and/or deaza analogues thereof, and analogues containing additional amino groups.
22. A nucleic acid synthesis building block having the general structural formulae (I) or (II):



wherein R¹ is an hydroxy protecting group,
R² is -H, -(C₁-C₁₀)-alkoxy, -(C₂-C₁₀)-alkenyloxy, -(C₂-C₁₀)-alkynyloxy, -
halogen, -azido, -NHR₇, -SR₇ or -OR₇, wherein R₇ is a protecting
group or a reporter group,
5 R³ is a phosphate, an H-phosphonate or other phosphate analogue
group which may contain a protecting group,
B is a nucleobase or a nucleobase analogue,
n is 0 or 1, and
L is a detectable protecting group.

10

23. Use of a building block of claim 22 for the production of nucleic acid
arrays.

15

24. A reagent kit for the synthesis of nucleic acid arrays comprising at
least one nucleic acid synthesis building block of claim 22.

20

25. The reagent kit of claim 24 comprising at least 2 nucleic acid
synthesis building blocks of claim 22 each carrying different
detectable protecting groups.

THIS PAGE BLANK (USPTO)

EPO - Munich
19. März 2003

Abstract

The invention relates to a quality control method for manufacturing
5 biopolymer arrays comprising the use of detectable protecting groups.

kt 19.03.2003

THIS PAGE BLANK (USPTO)

-1/2-

Figure 1



EPO - Munich
69
19. März 2003

Figure 2



-2/2-

Figure 3

